Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Female patients ≥ 18 years of age.~* Human epidermal growth factor receptor 2 (HER2)-negative cancer of the breast with locally recurrent or metastatic disease, suitable for chemotherapy.~* No adjuvant chemotherapy within 6 months before randomization, and no taxane-based chemotherapy within 12 months before randomization.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.~Exclusion criteria:~* Previous chemotherapy for metastatic or locally recurrent breast cancer.~* Radiotherapy for treatment of metastatic disease.~* Other primary tumors within last 5 years, except for controlled limited basal cell or squamous cancer of the skin, or cancer in situ of the cervix.~* Spinal cord compression or brain metastases.~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization.~* Inadequate bone marrow, liver, or renal function.~* Uncontrolled hypertension.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel 100 mg/m^2 plus placebo (Type: EXPERIMENTAL): Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
- Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg (Type: EXPERIMENTAL): Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
- Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg (Type: EXPERIMENTAL): Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).